DOD enlists Evotec subsidiary in antibody manufacturing program, awards up to $39M
The Department of Defense (DOD) has partnered with Just – Evotec Biologics, a Seattle-based subsidiary of Evotec, to enhance large-scale manufacturing capabilities under the DOD’s Manufacturing Optimization Program. With a multiyear award of up to $39 million, the subsidiary will create an accelerated framework for monoclonal antibody (mAb) production to significantly reduce manufacturing timelines.
In recent years, the DOD has worked with Just – Evotec Biologics several times to develop antibodies for various viral and bacterial threats, including COVID-19, mpox, and the bubonic plague. In a recent release, Linda Zuckerman, Ph.D., global head of biotherapeutics at Just- Evotec Biologics, stated that their team is “excited to push our current end-to-end biologics development platform and partner with the DOD to bring ‘next level’ development of fast, high quality, cost efficient mAbs to the clinic.”